Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

ABSTRACT:

Context

Attempts to determine the clinical significance of BRCA1/2 mutations in ovarian cancer have produced conflicting results.

Objective

To determine the relationships between BRCA1/2 deficiency (ie, mutation and promoter hypermethylation) and overall survival (OS), progression-free survival (PFS), chemotherapy response, and whole-exome mutation rate in ovarian cancer.

Design, setting, and patients

Observational study of multidimensional genomics and clinical data on 316 high-grade serous ovarian cancer cases that were made public between 2009 and 2010 via The Cancer Genome Atlas project.

Main outcome measures

OS and PFS rates (primary outcomes) and chemotherapy response (secondary outcome).

Results

BRCA2 mutations (29 cases) were associated with sign

SUBMITTER: Yang D 

PROVIDER: S-EPMC4159096 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature